

## PILOT TESTING CONFIRMS EFFICACY OF NEW LYME SUPPORT PROGRAM

For Immediate Release

VANCOUVER, BRITISH COLUMBIA – September 14, 2023 – Frequency Exchange Corp. (“Frequency Exchange” or the “Company”) (TSXV: FREQ ) is pleased to announce that its wholly-owned subsidiary, FREmedica Technologies Inc. (“FREmedica”), has achieved overwhelmingly positive results in pilot testing of a new hardware delivery device for its Lyme Frequency Support Program. The six-month trial compared results from the currently offered WAVE 1 frequency emitter and the newly launched watch-size NIKKI. This significant development is highly positive news for the company, and offers long-suffering Lyme-patients hope against the debilitating disease.

### Providing easier access to a highly acclaimed Lyme Frequency Support Program

60 participants chosen from Lyme Support Groups and Medical Centers across North America engaged in testing of a revolutionary Lyme support system protocol and the accompanying hardware designed to deliver the frequencies. The primary aim has been to create a user-friendly system with the ability to produce life-changing improvements in a short timeframe, while minimizing the occurrence of herxing. The test results unequivocally demonstrate that the NEW Lyme Frequency Support Program has not only performed exceptionally but has done so effectively on both the Wave 1 and NIKKI (trial) hardware.

### Easier access to the doctor-endorsed and user-acclaimed FREmedica Lyme Frequency Support Program

FREmedica tested a simplified Lyme Frequency Support Program, using two different frequency delivery systems; the current Wave 1 and NIKKI (the new wearable launched at the start of 2023). Based on these preliminary results, FREmedica plans on offering the Lyme Frequency Support Program on NIKKI on or before November 1st, 2023. Until the release of the Lyme Frequency Support Program on NIKKI the company has dedicated resources widening accessibility to the devices. They will offer a NIKKI free with every Wave 1 purchase while Wave 1 supplies last.

*“This is a very exciting time for our company. We continue to find ways to help make overcoming symptoms of Lyme disease easier for those who are struggling.”* **says FREmedica President Nicole Sullivan.** *“The launch of our New Lyme Frequency Support Program on the NIKKI will make it more accessible and much simpler for the user.”*



NIKKI +Lyme  
COMING SOON

### Testimonial from a Lyme Life Trial participant:

*The Lyme Frequency Support Program has given me back the hope of living without Lyme disease. It's only been a couple of months of using the Lyme Frequency Support Program and I feel like the fog has lifted and something has shifted. My body is starting to heal in ways I thought were no longer possible. I am excited about life again. I can feel myself getting a little stronger every day as my body begins to recover from years of chronic illness. I feel lighter and mentally sharper as well. I have to credit the stress and anxiety setting for getting me through the rough days. I have hope again as my energy comes back a little more each day. I know it's all just around the corner and I can't wait to live a full life of joy and fulfillment once again.”* - Allison B.



## About the Company

Based in British Columbia, Canada, FREmedica is focused on the development and global commercialization of a wearable Frequency Delivery System providing specialized programs designed for health and wellness as well as performance enhancement. NIKKI is the fifth-generation Frequency Delivery System released by the Company, initially to help clients with chronic Lyme disease. This wearable frequency technology is the product of years of research and development applying the latest in bioenergetic science.

[www.WeAreNikki.com](http://www.WeAreNikki.com)  
[www.Fremedica.com](http://www.Fremedica.com)  
[www.FrequencyExchangeCorp.com](http://www.FrequencyExchangeCorp.com)

For more information, please contact:

Frequency Exchange Corp.

Stephen Davis  
Chairman  
250-732-7170

FREmedica Technologies Inc.

Nicole Sullivan  
President  
[nicole@fremedica.com](mailto:nicole@fremedica.com)

## Cautionary Note Regarding Forward-Looking Information

Certain information contained herein constitutes "forward-looking information" under Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the trading date of the Company's common shares on the Exchange. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "will" or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.

Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available under the Company's profile on SEDAR at [www.sedar.com](http://www.sedar.com).

*Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.*